There is no single best prescription sleep medication for everyone. The right choice depends on whether you struggle to fall asleep, stay asleep, or both, along with your age, health history, and how you respond to a given drug. That said, several FDA-approved options have strong clinical backing, and understanding how they differ will help you have a more productive conversation with your doctor.
Why the “Best” Medication Varies by Sleep Problem
Insomnia broadly splits into two categories: trouble falling asleep (sleep onset) and trouble staying asleep (sleep maintenance). Some people deal with both. The American Academy of Sleep Medicine recommends different medications depending on which pattern you experience, and no single drug earned a strong recommendation for all types of insomnia. Every medication on the AASM’s list received a conditional recommendation, meaning the benefits are real but modest, and individual factors matter a lot.
This distinction is worth paying attention to. A medication designed to knock you out quickly but wear off fast won’t help much if your main problem is waking at 3 a.m. and staring at the ceiling. Conversely, a long-acting drug that helps you stay asleep could leave you groggy the next morning if your only issue is taking too long to drift off.
Z-Drugs: The Most Commonly Prescribed Options
Zolpidem (Ambien), eszopiclone (Lunesta), and zaleplon (Sonata) are the most widely prescribed sleep medications in the U.S. They work by enhancing a calming brain chemical to slow neural activity and promote drowsiness. In clinical trials, Z-drugs reduced the time it takes to fall asleep by about 22 minutes compared to placebo, as measured by sleep lab recordings.
These three drugs differ mainly in how long they last. Zaleplon has a half-life of roughly one hour, making it useful if you only need help falling asleep or if you wake in the middle of the night and still have several hours before your alarm. Zolpidem lasts about 2.5 to 3 hours in most people, covering sleep onset and the first stretch of the night. Eszopiclone lasts around six hours, making it the best Z-drug option for people who have trouble both falling and staying asleep.
The FDA added its most serious warning (a boxed warning) to all three Z-drugs after reports of complex sleep behaviors, including sleepwalking, sleep-driving, and performing activities while not fully awake. These events are rare but have led to serious injuries and deaths. If you’ve ever experienced a complex sleep behavior on one of these drugs, you should not take any of them again.
Orexin Receptor Antagonists: A Newer Approach
A newer class of sleep medications works by blocking orexin, a brain chemical that keeps you awake. Rather than sedating you directly, these drugs quiet the wakefulness signal, which tends to produce a more natural-feeling sleep. Three are currently FDA-approved: suvorexant (Belsomra), lemborexant (Dayvigo), and daridorexant (Quviviq).
A 2025 meta-analysis comparing lemborexant and daridorexant found both significantly improved sleep versus placebo, but lemborexant stood out. It reduced middle-of-the-night wakefulness by about 45 minutes compared to placebo, while daridorexant reduced it by about 13 minutes. Lemborexant also cut the perceived time to fall asleep by 25 minutes. These numbers make orexin antagonists particularly strong for sleep maintenance problems.
Suvorexant has a half-life of about 15 hours, which means next-day drowsiness is possible. Lemborexant and daridorexant have shorter durations. The orexin antagonists do not carry the same boxed warning for complex sleep behaviors as Z-drugs, though drowsiness and sleep paralysis are possible side effects.
Ramelteon: Gentlest on the System
Ramelteon (Rozerem) works differently from every other prescription sleep aid. It targets the same brain receptors as melatonin, reinforcing your body’s natural sleep-wake cycle rather than forcing sedation. It has no abuse potential and is not classified as a controlled substance, making it the only prescription sleep medication with that distinction.
The trade-off is potency. Ramelteon reduces the time to fall asleep by an average of about 13 minutes compared to placebo. People with a longer baseline time to fall asleep (more than about 67 minutes) tend to see bigger improvements, up to 23 minutes in some studies. It does not meaningfully help with staying asleep, so it’s best suited for people whose primary struggle is at the beginning of the night. Its half-life is about 2.5 hours, so next-day grogginess is uncommon.
Low-Dose Doxepin: Built for Staying Asleep
Doxepin (Silenor) is an older antidepressant that, at very low doses (3 to 6 mg rather than the 75 to 150 mg used for depression), selectively blocks a brain chemical involved in wakefulness. The AASM recommends it specifically for sleep maintenance insomnia. It helps people stay asleep through the night without the dependence risk associated with Z-drugs or benzodiazepines. Its half-life of about 15 hours means some people notice mild morning drowsiness, especially at first.
Trazodone: The Most Popular Off-Label Choice
Trazodone is technically an antidepressant, but its off-label use for insomnia has surpassed its use for depression. Doctors typically prescribe it at 25 to 50 mg for sleep, well below the antidepressant dose of 150 to 300 mg. At these low doses, its sedating properties dominate without the full antidepressant effect.
The evidence for trazodone is mixed. In a head-to-head trial of 306 adults, trazodone at 50 mg reduced the time to fall asleep during the first week, but by the second week its effect on sleep onset was no better than placebo. It performed better for sleep maintenance, helping people stay asleep through the night. Trazodone has a half-life of about 10 hours, so grogginess the next morning is a common complaint. Despite the thinner evidence base compared to FDA-approved sleep drugs, many doctors favor trazodone because it has no abuse potential and is inexpensive as a generic.
Benzodiazepines: Effective but Riskier
Temazepam (Restoril) and triazolam (Halcion) are the two benzodiazepines the AASM includes in its insomnia recommendations. Temazepam, with a half-life of roughly 4 to 18 hours, covers both sleep onset and maintenance. Triazolam acts faster and clears faster (half-life of 1.5 to 5.5 hours), making it better for sleep onset only.
Benzodiazepines are generally considered a second-line option today because of their higher risk of dependence, tolerance (needing higher doses over time), and rebound insomnia when stopped. They are also flagged on the Beers Criteria, a list of medications considered high-risk for adults over 65, due to increased odds of falls, confusion, and cognitive impairment. Older benzodiazepines like flurazepam and quazepam have extremely long half-lives (up to 100 hours for flurazepam) and are rarely prescribed for this reason.
Special Considerations for Older Adults
If you’re over 65, the medication landscape narrows considerably. The Beers Criteria flags benzodiazepines, antihistamines (including over-the-counter options like diphenhydramine), and barbiturates as high-risk for older adults due to impaired metabolism, confusion, falls, and delirium. Z-drugs also carry elevated risks in this group, and dosing is typically halved. Eszopiclone, for example, is capped at 2 mg for older adults versus 3 mg for younger patients.
Ramelteon, low-dose doxepin, and the orexin receptor antagonists are generally considered safer starting points for older adults because they carry lower risks of dependence, falls, and cognitive impairment.
How to Think About Choosing
A practical way to frame the decision:
- Trouble falling asleep only: Zaleplon, zolpidem, or ramelteon (if you prefer a non-controlled option).
- Trouble staying asleep only: Low-dose doxepin, lemborexant, or suvorexant.
- Both falling and staying asleep: Eszopiclone, lemborexant, or extended-release zolpidem.
- Concerned about dependence: Ramelteon, doxepin, or an orexin receptor antagonist, none of which produce the tolerance and withdrawal patterns seen with Z-drugs and benzodiazepines.
- Over 65: Ramelteon, low-dose doxepin, or an orexin antagonist, with cautious dosing.
No prescription sleep medication is meant to be a permanent fix. Most guidelines recommend using them alongside behavioral strategies, particularly cognitive behavioral therapy for insomnia (CBT-I), which addresses the root habits and thought patterns that sustain poor sleep. In clinical comparisons, CBT-I produces results that last longer than medication alone, and combining the two often works better than either approach by itself.